Treprostinil and Application site irritation - a phase IV clinical study of FDA data

Summary:

Application site irritation is reported as a side effect among people who take Treprostinil (treprostinil), especially for people who are female, 40-49 old, also take Ambrisentan, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Application site irritation when taking Treprostinil. It is created by eHealthMe based on reports of 7,695 people who have side effects when taking Treprostinil from the FDA, and is updated regularly.

What is Treprostinil?

Treprostinil has active ingredients of treprostinil. eHealthMe is studying from 7,695 Treprostinil users. Check the latest studies of Treprostinil.

What is Application site irritation?

Application site irritation is found to be associated with 387 drugs and 702 conditions by eHealthMe. Check the latest studies of Application site irritation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

7,695 people reported to have side effects when taking Treprostinil.
Among them, 20 people (0.26%) have Application site irritation.

Could Treprostinil cause Application site irritation?

Among these 20 people:

What is the gender of people who have Application site irritation when taking Treprostinil? *

female: 85 %
male: 15 %

What is the age of people who have Application site irritation when taking Treprostinil? *

What are other drugs people take besides Treprostinil? *

What are other side effects people have besides Application site irritation? *

Pain In Jaw: 14 people, 70.00%
Dyspnea (difficult or laboured breathing): 12 people, 60.00%
Skin Blushing/flushing (a sudden reddening of the face, neck): 11 people, 55.00%
Fainting (loss of consciousness and postural tone): 11 people, 55.00%
Skin Discoloration: 9 people, 45.00%
Hair Loss: 9 people, 45.00%
Skin - Clammy: 9 people, 45.00%
Heart Rate Increased: 9 people, 45.00%
Lung Disorder (lung disease): 9 people, 45.00%
Viral Infection: 9 people, 45.00%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 18 people, 90.00%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 5.00%
Malignant Atrophic Papulosis (an extremely rare vascular weakness that affects the lining of the medium and small veins and arteries): 1 person, 5.00%
Fainting (loss of consciousness and postural tone): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Treprostinil and have Application site irritation?

- Check whether Application site irritation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Treprostinil:

Treprostinil (7,695 reports)

Browse all side effects of Treprostinil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site irritation:

Application site irritation (387 drugs)

Browse all the conditions that are associated with Application site irritation:

Application site irritation (702 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil (the active ingredients of Treprostinil) and Treprostinil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.